Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

109.35 +0.95 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
42 43 Next >
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology. 
Via Benzinga
3 Biotech Companies to Watch in 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
Via InvestorPlace
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy Right Now
These two pharmaceutical companies pay market-beating dividends to shareholders. 
Via The Motley Fool
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' 
Via Benzinga
Hopeful Golden Cross Forms On Novartis's Chart
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
A Bullish Sign Appears On Novartis's Chart
Via Benzinga
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
These two biotechs are flying high right now. 
Via The Motley Fool
Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories
Reuters 
Via Benzinga
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial
Via Benzinga
3 Ridiculously Cheap Dividend Stocks That Yield More Than 3%
You're getting a lot of bang for your buck with these stocks. 
Via The Motley Fool
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI... 
Via Benzinga
A Career Politician Who Regularly Trades The SPY, Picked Up There 3 High Yielding ETFs Instead
Representative Robert Wittman (R-VA) is the vice-ranking member of the House Armed Services Committee and also serves on the Committee on Natural Resources. 
Via Benzinga
Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder
Via Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. 
Via InvestorPlace
Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
Via Benzinga
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
From Erasca, Inc.
Via GlobeNewswire
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs
Via Benzinga
Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo
Via Benzinga
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
Via Investor Brand Network
Exposures COVID-19
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
Exposures Product Safety
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
By Rachael Green, Benzinga 
Via News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... 
Via TheNewswire.com
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.